China In-Vitro Diagnosis Industry Indepth Research and Investment Strategy Planning Report, 2013-2017
A must-have for enterprise medium to long-term strategic planning
Without deep industry knowledge, it will be difficult to gain any return
The Ministry of Commerce of the People's Republic of China designated Qianzhan Industrial Research Institute as the only "regional workstation for dealing with trade friction" in the Guangdong-Hong Kong-Macao Greater Bay Area
We are aware of that the content of our products have been stolen by some ones who changed the design and used it to deceive customers as it is their own products. Customers who are misled may experience no product received or an incomplete product. Therefore, Qianzhan Industrial Research Institute encourage you to arrange an in-person visit to our company before you make the purchase. Qianzhan has the sole copyright of all research reports. We have never had partnership or affiliated with any third party agent. Please recognize the""trademark when purchasing reports.To have better investment return or strategic outcomes, you must have a forward-looking vision. Qianzhan Industrial Research Institute - China's leading industry consulting institutions provide you with all the things you need in business!
* The table of contents and the rest of this report are originally created by Qianzhan. Without any prior written permission, it is prohibited to copy or reproduce in any way. To have better investment return or strategic outcomes, you must have a forward-looking vision!
Table of Contents
China IVD industry is now in the early development phase. The industry has huge space for development. There are more than 20,000 hospitals, 530 blood stations, the ever-changing health examination centers and the emerging independent clinic labs in China, which provide huge maker demand for IVD industry.
With the development of modern laboratory medicine, in-vitro diagnosis industry (IVD industry) comes into being. In reverse, it promotes the rapid development of laboratory, preclinical medicine and other disciplines. At present, 2/3 medical decisions have been made on the basis of diagnostic message in the world, while the diagnostic income occupies only 1% of the total medical expense. The further improvement of diagnostic technologies to disease prevention, diagnosis and treatment has positive meaning, and the diagnostic reagent industry has vast space for development.
IVD industry is always one of key supporting industries in domestic. Since 2005, the State Council, the National Development and Reform Committee, the Ministry of Science and Technology issued many policies, which play a positive role in promoting the development of diagnostic reagent, diagnostic equipment, and enzymic preparations related to diagnosis, and which also strengthen the competitiveness of domestic diagnostic reagent enterprises.
Since 2006, the domestic IVD industry has shown the rapid growth of the annual increase rate of around 15%. According to statistics, the market size of China IVD industry in 2008 reached 9.5 billion Yuan, and it increased to 12.2 billion Yuan in 2010. It’s predicted the market size of IVD industry will maintain at an increase rate of around 15%. By 2015, the market size of China IVD industry is anticipated to exceed 30 billion Yuan, which is expected to the third market in the world, with an average increase rate between 15% and 20%.
In recent years, the high-speed growth and high profit characteristic of IVD industry attract a group of enterprises rushing into this field. The gross profit rate of national enterprises in this industry is around 50%, such as Biosino Bio-technology and Science Inc., which listed in Hong Kong, Shanghai Kehua Bio-Engineering Co., Ltd. and Da An Gene Co., Ltd., which listed in Guangzhou, and Shenzhen), which listed in NYSE.
The local leading enterprises both accelerate to implement the diversification development strategies, and keep investing in IVD projects. At the end of February 2012, BioSino Bio-technology and Science Inc. and Abbott, a leading diversification healthcare company, announced that they had signed the sales and delivery cooperative projects together. On January 16th, the DA An Gene, a leading high-tech enterprise oriented in molecular diagnostic techniques, announced to invest 14.88 million Yuan, to sign cooperative contract with Life Technologies, whose headquarter locates in California, USA, for establishing early diagnosis on cancer, infectious disease and inherited disease.
Overall, China IVD industry is now in the early development phase. The industry has huge space for development. There are more than 20,000 hospitals, 530 blood stations, the ever-changing health examination centers and the emerging independent clinic labs in China, which provide huge maker demand for IVD industry. From the perspective of customers, the goal market of IVD reagents has shifted from focusing on hospital to the equal development of hospital, third party healthcare examinations centers and families. With the increasing prevention and precaution awareness of residents, and with the increase of high and middle-income earners and long-term supervision groups, the home diagnosis reagent will show its explosive growth.
In addition, with the deepening of new healthcare reform and with growing attention to people’s livelihood, the primary hospitals bring huge growth for IVD industry. The State invests in primary health system with as high as 100 billion Yuan, and the most beneficial industry segments is the common products for biochemical reagents. All in all, many industry segments of diagnosis reagents all have investment opportunities, while home diagnosis reagents will be a focus in the future.
Qianzhan Business Information Co., Ltd. Industry Research Center
Research Team of IVD Industry
The National Bureau of Statistics Foreign-related investigation Permission
National Innovation Company and Dual Software Certified Enterprise
The only DRC desginated Enterprise of the Industry Yearbook
National Ministry of Commerce designated Industrial Early Warning and Monitoring Workstation
Guangdong Province Enterprise of Observing Contract and Valuing Credit
Qianzhan is an industry consulting service provider with national innovation company qualification, independent research and development of industrial big data and Dual Software Certification.
Qianzhan is a consulting and research organization that has been engaged in business consulting for over 16 years in China.
Qianzhan is a consulting service provider with a team of nearly 300 industrial researchers and analysts.
Qianzhan is a consulting service provider with an in-house expert pool of 1200 experts.
Qianzhan is a research and consulting organization that have served 180000 clients and received over positive comments from 100000 of our clients.
Qianzhan is an industry research and consulting organization that has been designated by the highest authority, the DRC, to prepare the yearbook.
Qianzhan is an industry planning and consulting organization that adopts the internationally synchronized SCP scientific analysis model and the perfect industry chain research map to guide the business planning and consulting.
Qizhan is a consulting service organization that helps enterprises to solve the five aspects of industry research, planning, strategic design, capital operation and implementation.
Free Hotline：+86 400-068-7188
Customer Hotline：+86 755 - 82925195 / 82925295
3rd Floor, FIYTA Building West, High Tech South Avenue 1, Nanshan District, Shenzhen, China
Location：Rm.1106, Building 1, Jiayu International Plaza, Songhu Road, Yangpu District,
Offer a forward-looking vision to all of our customers.
We welcome any feedbacks and suggestions to make our customers 100% satisfied.
Having more than 20 qualification certificates, including Innovation Company Certificate and Foreign-related investigation Permission etc.
Thank you for recognizing our high quality products and professional, rigorous and sincere service.